医学
超声乳化术
青光眼
外围设备
眼科
闭角型青光眼
结束语(心理学)
内科学
视力
经济
市场经济
作者
Liqing Wei,Лин Фу,Li Nie,Hengli Lian,Zhenbin Qian,Yuanbo Liang,Weihua Pan
出处
期刊:Journal of Glaucoma
[Ovid Technologies (Wolters Kluwer)]
日期:2022-05-10
卷期号:31 (7): 540-546
被引量:4
标识
DOI:10.1097/ijg.0000000000002050
摘要
Phacoemulsification and goniosynechialysis (Phaco-GSL) was equally effective in the treatment of primary angle-closure disease (PACD) with preoperative peripheral anterior synechiae (PAS) <180 degrees and larger than 180 degrees. Patients with a larger preoperative PAS range required more range of mechanical separation intraoperatively and displayed more recurrence of PAS (re-PAS) range postoperatively.To evaluate the long-term efficacy of combined phaco-GSL in PACD with different extent of PAS.A retrospective study was conducted on 67 patients (79 eyes) who received phaco-GSL. The patients were divided into 2 groups according to the extent of PAS (group A: PAS ≤180 degrees; group B: PAS >180 degrees). Changes in intraocular pressure (IOP), the number of anti-glaucoma drugs, intraoperative mechanical separation of PAS and range of re-PAS during the last follow-up ≥12 months were analyzed.At baseline, eyes in group B presented with higher IOP and more anti-glaucoma drugs usage ( P =0.008 and 0.004). The PAS range, IOP, number of anti-glaucoma medication were reduced both in 2 groups at the final visit. The range of mechanical separation intraoperatively and re-PAS postoperatively were both larger in group B ( P =0.002 and <0.001). The postoperative re-PAS range was positively correlated with the range of mechanical separation ( R2 =0.17). The complete success rates at 12, 24, 36, and 48 months were 86.8%, 71.1%, 71.1%, and 71.1% in group A; and 80.5%, 74.6%, 69.9%, and 69.9% in group B. The qualified success rates were 100%, 96.6%, 92.0%, and 92.0% in group A; and 100%, 89.5%, 85.1%, and 85.1% in group B.Phaco-GSL for the treatment of PACD showed equally effective IOP control regardless of the extent of preoperative PAS.
科研通智能强力驱动
Strongly Powered by AbleSci AI